title: Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial.
abstract: OBJECTIVE
  The efficacy and safety of blood pressure lowering in elderly patients have not been sufficiently investigated in patients with diabetes. Using data from the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation study, we assessed the efficacy and safety of routine blood pressure lowering to prevent major clinical outcomes in elderly patients with type 2 diabetes.
  
  
  METHODS
  Eleven thousand one hundred and forty patients aged at least 55 years with type 2 diabetes (mean 66+/-6 years) were randomly assigned to perindopril-indapamide or placebo. The primary endpoint was a composite of major macrovascular and microvascular disease. The effects of active treatment on outcomes were estimated in subgroups according to age: below 65, 65-74 and at least 75 years.
  
  
  RESULTS
  During a mean 4.3-year follow-up, 1799 (16.1%) patients experienced a major event. Active treatment produced similar relative risk reductions for the primary outcome, major macrovascular disease, death and renal events across age groups (all P heterogeneity >0.3). Over 5 years, active treatment was estimated to prevent one primary outcome in every 21, 71 and 118 patients of at least 75, 65-74 and below 65 years, respectively. Similar patterns of benefits were observed for secondary outcomes. There were no differences in the tolerability between randomized allocations across age groups (all P heterogeneity >0.6)
  
  
  CONCLUSIONS
  Routine administration of perindopril-indapamide lowers blood pressure safely and reduces the risk of major clinical outcomes in patients of at least 75 years with type 2 diabetes. The greater absolute benefits in older patients in this age group were not offset by an increased risk of side effects.
authors.affiliation: The George Institute for International Health, University of Sydney, New South Wales, Australia.
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Ninomiya
authors.forename: Sophia
authors.initials: S
authors.lastname: Zoungas
authors.forename: Bruce
authors.initials: B
authors.lastname: Neal
authors.forename: Mark
authors.initials: M
authors.lastname: Woodward
authors.forename: Anushka
authors.initials: A
authors.lastname: Patel
authors.forename: Vlado
authors.initials: V
authors.lastname: Perkovic
authors.forename: Alan
authors.initials: A
authors.lastname: Cass
authors.forename: Mark
authors.initials: M
authors.lastname: Cooper
authors.forename: Diederick
authors.initials: D
authors.lastname: Grobbee
authors.forename: Pavel
authors.initials: P
authors.lastname: Hamet
authors.forename: Stephen
authors.initials: S
authors.lastname: Harrap
authors.forename: Lisheng
authors.initials: L
authors.lastname: Liu
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mancia
authors.forename: Carl-Erik
authors.initials: CE
authors.lastname: Mogensen
authors.forename: Neil
authors.initials: N
authors.lastname: Poulter
authors.forename: Anthony
authors.initials: A
authors.lastname: Rodgers
authors.forename: Bryan
authors.initials: B
authors.lastname: Williams
authors.forename: Stephen
authors.initials: S
authors.lastname: MacMahon
authors.forename: John
authors.initials: J
authors.lastname: Chalmers
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007190:Indapamide / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020913:Perindopril / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos
chemical_list: D000959:Antihypertensive Agents; D010919:Placebos; D007190:Indapamide; D020913:Perindopril